The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC)
The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic urothelial cancer (mUC) has rapidly changed in the last year alone. Maintenance avelumab remains a viable treatment option for many patients across the globe for those who have responded or have achi...
Saved in:
Main Authors: | Minira Aslanova (Author), Eun-Mi Yu (Author), Jeanny B. Aragon-Ching (Author) |
---|---|
Format: | Book |
Published: |
Open Exploration Publishing Inc.,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China
by: Kehui Meng, et al.
Published: (2024) -
Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder
by: Ipek Isik Gonul, et al.
Published: (2018) -
Metastatic urothelial carcinoma
by: Elisabeth Gómez-Moyano, et al.
Published: (2021) -
Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024) -
Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy
by: Min Woo Hwang, et al.
Published: (2024)